Bionano Genomics, Inc. (BNGO) intrinsic value & 10-year financials
Bionano Genomics, Inc. (BNGO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 14.7% a year to $28.5M, with an average return on invested capital of -144.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.25
- Market cap
- $6.8M
- Revenue (FY2025)
- $28.5M
- Revenue growth (10-yr CAGR)
- 14.7%
- ROIC (10-yr avg)
- -144.9%
- Free cash flow (FY2025)
- -$16.3M
BNGO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $28.5M | -$26.4M | -$4.85 | -$16.3M | -116.9% | -86.3% |
| FY2024 | $30.8M | -$112.0M | -$88.13 | -$69.0M | -337.9% | -180.4% |
| FY2023 | $36.1M | -$232.5M | -$6.81 | -$126.9M | -596.0% | -127.1% |
| FY2022 | $27.8M | -$132.6M | -$0.46 | -$127.2M | -473.7% | -45.8% |
| FY2021 | $18.0M | -$72.4M | -$0.26 | — | -428.8% | -42.7% |
| FY2020 | $8.5M | -$41.1M | — | -$38.3M | -453.4% | -398.5% |
| FY2019 | $10.1M | -$29.8M | — | -$29.6M | -255.4% | -573.0% |
| FY2018 | $12.0M | -$18.5M | — | -$20.3M | -170.1% | 97.5% |
| FY2017 | $9.5M | -$23.4M | — | -$21.8M | -244.3% | 52.2% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Bionano Genomics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Bionano Genomics, Inc. has historically struggled to out-earn its cost of capital, averaging just -18.2% ROIC.
Bionano Genomics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Bionano Genomics, Inc. is modeled at 14.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-158.75 per share.